RVPH CFO awarded 40,925 stock options

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Rhea-AI Filing Summary

REVIVA PHARMACEUTICALS HOLDINGS, INC. Chief Financial Officer Prabhu Narayan received a grant of stock options covering 40,925 shares of common stock on the grant date of March 18, 2026. These options have an exercise price of $1.87 per share and expire on March 17, 2036.

The award vests over time under the company’s 2020 Equity Incentive Plan. Of the total, 12,789 option shares vested immediately on the grant date, while the remaining 28,136 shares will vest in equal monthly installments from April 2026 through December 2028, encouraging long-term alignment with the company.

Insider Trade Summary

Grant/Award: 40,925 shares

Grant/Award 1 txn

Insider Prabhu Narayan

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	40,925	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 40,925 contracts (Direct)

Footnotes (1)

1. F1. This option award was made on March 18, 2026 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The option provides for vesting as follows: (i) 12,789 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 28,136 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did RVPH CFO Prabhu Narayan report in this Form 4 filing?

CFO Prabhu Narayan reported receiving a grant of stock options for 40,925 shares of Reviva Pharmaceuticals common stock. The grant is part of the 2020 Equity Incentive Plan, with a portion vested immediately and the rest vesting monthly through December 2028.

What are the key terms of Prabhu Narayan’s RVPH stock option grant?

The stock option covers 40,925 shares at an exercise price of $1.87 per share and expires on March 17, 2036. It was granted under Reviva’s 2020 Equity Incentive Plan as compensation, not as an open-market purchase or sale of shares.

How do the RVPH stock options granted to the CFO vest over time?

Of the 40,925 options, 12,789 vested immediately on the March 18, 2026 grant date. The remaining 28,136 options will vest in equal installments on the last day of each month from April 2026 through December 2028, creating a multi-year vesting schedule.

Did the RVPH CFO buy or sell common shares in this Form 4?

No common share purchases or sales were reported. The Form 4 shows only a grant of stock options, a derivative security, to CFO Prabhu Narayan as compensation. It reflects an acquisition of options rather than an open-market transaction in existing common shares.

How many RVPH stock options does the CFO hold after this transaction?

After the reported grant, CFO Prabhu Narayan holds 40,925 stock options directly, according to the filing. These options relate to Reviva Pharmaceuticals common stock and are subject to the vesting schedule and expiration terms disclosed for this specific award.

What plan governs the RVPH stock option grant to the CFO?

The grant was made under Reviva Pharmaceuticals’ 2020 Equity Incentive Plan. The plan sets terms such as using the grant date closing stock price for the $1.87 exercise price and establishing the immediate and monthly vesting schedule through December 2028 for this option award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/20/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Prabhu Narayan

(Last) (First) (Middle)

C/O REVIVA PHARMACEUTICALS HOLDINGS, INC

10080 N. WOLFE RD., SUITE SW3-200

(Street)

CUPERTINO CALIFORNIA 95014

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
REVIVA PHARMACEUTICALS HOLDINGS, INC. [ RVPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.87	03/18/2026		A		40,925		(1)	03/17/2036	Common Stock, par value $0.0001 per share	40,925	$0	40,925	D

Explanation of Responses:

1. This option award was made on March 18, 2026 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The option provides for vesting as follows: (i) 12,789 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 28,136 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan.

	/s/ Narayan Prabhu	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)